Posted by Michael Wonder on 30 May 2023
Inhibrx granted fast track designation for INBRX-101 for the treatment of alfa-1 antitrypsin deficiency
30 May 2023 - Inhibrx announced today that the US FDA granted fast track designation to INBRX-101, an optimised recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 anti-trypsin deficiency.
INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of alfa-1 anti-trypsin found in healthy individuals with the potential for a less frequent dosing interval compared to the weekly infusion interval of the currently available plasma derived AAT therapies.
